Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: ragged (23), shabby (1)

Rifampicin and clindamycin for hidradenitis suppurativa in adults - patient information

Description: This factsheet explains what rifampicin and clindamycin are, how to take the medicines and the possible side effects.
Url: /Media/UHS-website-2019/Patientinformation/Skin/Rifampicin-and-clindamycin-for-hidradenitis-suppurativa-in-adults-3649-PIL.pdf

Blood loss – what to expect after the birth of your baby - patient information

Description: This factsheet provides information about after pains and postnatal blood loss (lochia) in the days and weeks after your baby's birth
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Blood-loss-what-to-expect-after-the-birth-of-your-baby-743a-PIL.pdf

Papers Trust Board - 27 July 2023

Description: Date Time Location Chair Agenda Trust Board – Open Session 27/07/2023 9:00 - 13:15 Conference Room, Heartbeat/Microsoft Teams
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Papers-Trust-Board-27-July-2023.pdf

UHS adult major trauma guidelines

Description: Adult Major Trauma Guidelines University Hospital Southampton NHS Foundation Trust Dr Mark Baxter Director of Major Trauma, Consultant in Older Persons
Url: /Media/SUHTExtranet/WessexTraumaNetwork/UHS-adult-major-trauma-guidelines.pdf

Docetaxel-Nintedanib v1

Description: Chemotherapy Protocol NSCLC CANCER DOCETAXEL-NINTEDANIB Regimen NSCLC – Docetaxel-Nintedanib Indication Advanced or metastatic NSCLC of adenocarcinoma origin that has progressed
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Docetaxel-Nintedanib-v1.pdf

Docetaxel (100) Ver 1.1

Description: Chemotherapy Protocol BREAST CANCER Regimen DOCETAXEL (100) Breast Cancer – Docetaxel (100) Indication Neoadjuvant / adjuvant treatment of breast cancer WHO Performance status
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Docetaxel-100-Ver-11.pdf

Cyclophosphamide-Docetaxel-Doxorubicin Ver 1.1

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-DOXORUBICIN Regimen (TAC) Breast Cancer – Cyclophosphamide-Docetaxel-Doxorubicin (TAC) Indication Adjuvant therapy for node positive
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/BreastCyclophosphamideDocetaxelDoxorubicinTACVer11.pdf

Cyclophosphamide-Docetaxel Ver 1.1

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL Regimen Breast Cancer – Cyclophosphamide-Docetaxel Indication Adjuvant therapy for early breast cancer when anthracyclines are
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/BreastCyclophosphamideDocetaxelVer11.pdf

Cisplatin and Docetaxel

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-DOCETAXEL Regimen Uterine-Cisplatin-Docetaxel Indication Recurrent/advanced uterine cancer Palliative intent WHO performance status 0
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/CisplatinDocetaxel.pdf

Oesophageal manometry test and 24-hour pH and impedance measurement test - Patients off proton pump inhibitors (PPIs) - patient information

Description: This factsheet explains what an oesophageal manometry test and a 24-hour pH and impedance measurement test are and what they
Url: /Media/UHS-website-2019/Patientinformation/Tests/Oesophageal-manometry-test-and-24-hour-pH-and-impedance-measurement-test-Patients-off-proton-pump-inhibitors-PPIs-3729-PIL.pdf

51 to 60 of 81

Previous … 4 5 6 7 8 … Next